Skip to main content
. Author manuscript; available in PMC: 2009 Sep 22.
Published in final edited form as: Oncogene. 2008 Apr 14;27(34):4702–4711. doi: 10.1038/onc.2008.109

Figure 2.

Figure 2

Growth inhibition of lung cancer cell lines by BIBW2992 and other EGFR and/or HER2 inhibitors (a) Sensitivity of NSCLC cell lines that express EGFR WT, Exon 19 Del, L858R/T790M and HER2 INS776V to BIBW2992 and erlotinib. Dose-dependent growth inhibition was determined by MTS assay. Only HCC827 cells are sensitive to erlotinib whereas NCI-H1781 and NCI-H1975 cells are also sensitive to BIBW2992. Points, average of two independent experiments, each done in triplicate; bars, s.d. *A549 cells harbor a Kras G12S mutation. See also in Supplementary Table 4. (b) Inhibition of anchorage independent cell proliferation of various lung cancer cell lines treated with BIBW2992, lapatinib, canertinib, gefitinib or erlotinib. The IC50 values were determined as described in ‘Materials and methods’, confirmed in independent experiments and reported as nM values. H1666 express wild-type EGFR, H3255 express the EGFR L858R mutant and NCI 1975 express the EGFR L858R/T790M double mutant.